Hematopoietic Support by Adipose-Derived Stromal Cells

脂肪源性基质细胞的造血支持

• 批准号: 6435095
• 负责人: Jeffrey Martin Gimble
• 金额: $ 10万
• 依托单位: ARTECEL SCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-06-18 至 2001-12-17
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6435095
• 关键词: adipose tissue; bone marrow; cell differentiation; cell proliferation; cell sorting; hematopoietic tissue; human tissue; tissue /cell culture

Bone marrow transplantation requires large numbers of pluripotent hematopoietic stem cells to achieve a successful clinical outcome. Therefore, there is a pressing medical need for methods to expand stem cells ex vivo and accelerate their engraftment in vivo. These steps may be supported by cytokine-producing stromal cells. The scientists at Artecel Sciences have developed proprietary techniques to isolate and culture human stromal cells from adipose tissue that can be used for autologous and allogeneic transplantation. This SBIR investigates the hypotheses that adipose derived stromal cells will (1) support hematopoietic progenitor cell proliferation and differentiation in vitro and (2) accelerate their engraftment in vivo. Aim 1 (Phase I) will demonstrate that human adipose derived stromal cells will support proliferation of multipotent and pluripotent hematopoietic progenitors in short and long term cultures using flow cytometric and methylcellulose assays. This work provides a foundation for Phase H studies to determine: (Aim 3) The ability of ex vivo expanded hematopoietic progenitors to repopulate sublethally irradiated NOD/SCID mice; (Aim 4) The ability of adipose derived stromal cells to accelerate hematopoietic stem cell engraftment in sublethally irradiated NOD/SCID mice. PROPOSED COMMERCIAL APPLICATION: This SBIR will develop technology with application to all patients receiving bone marrow transplantation. Each year, 20,000+ patients under this therapy at an individual cost of $100,000. Artecel Sciences technology has the potential to significantly reduce the clinical and financial burden of these procedures.

骨髓移植需要大量的多能造血干细胞， 干细胞来获得成功的临床结果。因此，有一个紧迫的 医学上需要离体扩增干细胞并加速其 体内植入。这些步骤可以由产生精氨酸的基质支持。 细胞Artecel Sciences的科学家开发了专有技术， 从脂肪组织中分离和培养人基质细胞， 自体和同种异体移植。本SBIR研究假设 脂肪来源的基质细胞将（1）支持造血祖细胞 体外增殖和分化以及（2）促进它们在体内的植入。 目的1（I期）将证明人脂肪来源的基质细胞将 支持多能和多能造血祖细胞增殖， 使用流式细胞术和甲基纤维素测定进行短期和长期培养。这 工作为H阶段研究提供了基础，以确定：（目标3） 离体扩增的造血祖细胞以使亚致死辐射的 NOD/SCID小鼠;（目的4）脂肪来源的基质细胞加速细胞增殖的能力 造血干细胞移植在亚致死照射的NOD/SCID小鼠中。 拟定商业应用： 该SBIR将开发适用于所有接受骨移植的患者的技术 骨髓移植每年有20，000多名患者接受这种治疗， 个人费用10万元。Artecel Sciences技术有潜力 大大减轻了这些手术的临床和经济负担。